Drugs / IN006
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT06287450 | Dec 2026 → Apr 2028 expected | respiratory syncytial virus infectious disease | Shenzhen Shenxin Biotechnology Co., Ltd | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT06645665 | Nov 2024 → Apr 2027 expected | respiratory syncytial virus infectious disease | Shenzhen Shenxin Biotechnology Co., Ltd | Active not recruiting | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT07128121 | Aug 2025 → Oct 2029 expected | respiratory syncytial virus infectious disease | Shenzhen Shenxin Biotechnology Co., Ltd | Active not recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IN006 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06287450 ↗ |
| Known as | Bivalent RSV Vaccine (IN006) | “Bivalent RSV Vaccine (IN006)” NCT06287450 ↗1“Bivalent RSV Vaccine (IN006)” NCT06645665 ↗ |
| Modality | Messenger RNA (mRNA) | “Bivalent mRNA Vaccine (IN006)” NCT06287450 ↗ |